Key result
Incomplete or absent echocardiographic recovery at 6 months independently predicted chronic thromboembolic pulmonary hypertension or post-PE impairment at long-term follow-up (adjusted OR 7.14).
Why the study?
Guidelines lack specific recommendations on which patients to follow after acute PE, follow-up timing, and testing, while predictors of late PE sequelae remain undetermined.
Does incomplete echocardiographic recovery at 6 months predict long-term CTEPH or post-PE impairment in survivors of acute intermediate-risk pulmonary embolism?
Observational (n=219)
Double-blind
Randomized
Yes
Does incomplete echocardiographic recovery at 6 months predict long-term CTEPH or post-PE impairment in survivors of acute intermediate-risk pulmonary embolism?
Effect estimate: OR 1.19 (95% CI 0.54-2.62)
Absolute Event Rate: 14.3% vs 12.1%
p-value: p=0.67
Incomplete echocardiographic recovery at 6 months after acute intermediate-risk pulmonary embolism strongly predicts the development of chronic thromboembolic pulmonary hypertension or post-PE impairment at long-term follow-up.
Supports 6-month echocardiography for risk stratification after intermediate-risk PE; hypothesis-generating for targeted follow-up trials.
INTRODUCTION: Symptoms and functional limitation are frequently reported by survivors of acute pulmonary embolism (PE). However, current guidelines provide no specific recommendations on which patients should be followed after acute PE, when follow-up should be performed, and which tests it should include. Definition and classification of late PE sequelae are evolving, and their predictors remain to be determined. METHODS: In a post hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial, we focused on 219 survivors of acute intermediate-risk PE with clinical and echocardiographic follow-up 6 months after randomisation as well as over the long term (median, 3 years after acute PE). The primary outcome was a composite of (1) confirmed chronic thromboembolic pulmonary hypertension (CTEPH) or (2) 'post-PE impairment' (PPEI), defined by echocardiographic findings indicating an intermediate or high probability of pulmonary hypertension along with New York Heart Association functional class II-IV. RESULTS: Confirmed CTEPH or PPEI occurred in 29 (13.2%) patients, (6 with CTEPH and 23 with PPEI). A history of chronic heart failure at baseline and incomplete or absent recovery of echocardiographic parameters at 6 months predicted CTEPH or PPEI at long-term follow-up. CONCLUSIONS: CTEPH or PPEI occurs in almost one out of seven patients after acute intermediate-risk PE. Six-month echocardiographic follow-up may be useful for timely detection of late sequelae.
No takes yet. Share an insight, caveat, or question.
Barco et al. (2018) conducted an observational in Acute intermediate-risk pulmonary embolism (n=219). Tenecteplase vs. Placebo was evaluated on Confirmed chronic thromboembolic pulmonary hypertension (CTEPH) or post-PE impairment (PPEI) (OR 1.19, 95% CI 0.54-2.62, p=0.67). Incomplete or absent echocardiographic recovery at 6 months independently predicted chronic thromboembolic pulmonary hypertension or post-PE impairment at long-term follow-up (adjusted OR 7.14).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: